MK-2206

Generic Name: MK-2206

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₂₁N_₅O

CAS Number: 1032349-93-1

Unique Ingredient Identifier: 51HZG6MP1K

Clinical Trials

MK-2206 for Recurrent Malignant Glioma

Phase 2

Withdrawn

Conditions: Malignant Glioma

Interventions: Drug: MK-2206

First Posted Date: 2010-11-29

Last Posted Date: 2016-03-10

Lead Sponsor: Dana-Farber Cancer Institute

Registration Number: NCT01249105

Locations: 🇺🇸
UCLA Medical Center, Los Angeles, California, United States
🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸
Memorial Sloan Kettering, New York, New York, United States

and more 2 locations

BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: AZD6244
Drug: Erlotinib
Drug: Sorafenib
Drug: MK-2206

First Posted Date: 2010-11-25

Last Posted Date: 2022-01-12

Lead Sponsor: M.D. Anderson Cancer Center

Target Recruit Count: 334

Registration Number: NCT01248247

Locations: 🇺🇸
Yale Universtiy, New Haven, Connecticut, United States
🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States

Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer

Phase 1

Completed

Conditions: HER2-positive Breast Cancer
Recurrent Breast Cancer
Stage IIIB Breast Cancer
Male Breast Cancer
Stage IIIC Breast Cancer
Stage IV Breast Cancer
Unspecified Adult Solid Tumor, Protocol Specific

Interventions: Drug: Akt inhibitor MK2206
Drug: lapatinib ditosylate
Other: pharmacological study
Other: laboratory biomarker analysis

First Posted Date: 2010-11-22

Last Posted Date: 2014-10-23

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 28

Registration Number: NCT01245205

Locations: 🇺🇸
University of Wisconsin Hospital and Clinics, Madison, Wisconsin, United States
🇺🇸
Sanford Cancer Center-Oncology Clinic, Sioux Falls, South Dakota, United States

A Study of Dalotuzumab + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + Ridaforolimus Combination Therapies in Participants With Advanced Cancer (MK-0646-027)

Phase 1

Terminated

Conditions: Neoplasms Malignant

Interventions: Drug: dalotuzumab
Drug: MK-0752
Drug: MK-2206
Drug: ridaforolimus

First Posted Date: 2010-11-19

Last Posted Date: 2018-08-16

Lead Sponsor: Merck Sharp & Dohme LLC

Target Recruit Count: 47

Registration Number: NCT01243762

Trial of MK-2206 + Endocrine Treatment in Patients With Hormone Receptor Positive Breast Cancer

Phase 2

Withdrawn

Conditions: Metastatic Breast Cancer

Interventions: Drug: MK-2206
Drug: Exemestane
Drug: Goserelin

First Posted Date: 2010-11-15

Last Posted Date: 2013-08-20

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Registration Number: NCT01240941

MK2206 in Treating Patients With Advanced Liver Cancer That Did Not Respond to Previous Therapy

Phase 2

Terminated

Conditions: Advanced Adult Hepatocellular Carcinoma
Adult Hepatocellular Carcinoma
Recurrent Adult Liver Carcinoma
Localized Non-Resectable Adult Liver Carcinoma

Interventions: Drug: Akt Inhibitor MK2206
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-11-11

Last Posted Date: 2015-10-05

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 15

Registration Number: NCT01239355

Locations: 🇺🇸
NorthShore University HealthSystem-Evanston Hospital, Evanston, Illinois, United States
🇺🇸
USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
University of Chicago Comprehensive Cancer Center, Chicago, Illinois, United States

and more 19 locations

Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer

Phase 2

Terminated

Conditions: Metastatic Kidney Carcinoma
Recurrent Renal Cell Carcinoma
Stage IV Renal Cell Cancer AJCC v7
Stage III Renal Cell Cancer AJCC v7

Interventions: Drug: Akt Inhibitor MK2206
Drug: Everolimus
Other: Laboratory Biomarker Analysis

First Posted Date: 2010-11-11

Last Posted Date: 2019-10-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 43

Registration Number: NCT01239342

Locations: 🇺🇸
USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸
Tower Cancer Research Foundation, Beverly Hills, California, United States
🇺🇸
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States

and more 5 locations

MK-2206, Paclitaxel and Trastuzumab in Treating Patients With HER2-overexpressing Solid Tumor Malignancies

Phase 1

Completed

Conditions: Cancer
Advanced Solid Tumors
Tumors

Interventions: Drug: MK-2206
Drug: Paclitaxel
Drug: Trastuzumab

First Posted Date: 2010-11-07

Last Posted Date: 2014-04-17

Lead Sponsor: University of California, San Francisco

Target Recruit Count: 17

Registration Number: NCT01235897

Locations: 🇺🇸
University of California, San Francisco, San Francisco, California, United States

MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia

Phase 1

Completed

Conditions: Accelerated Phase Chronic Myelogenous Leukemia
Acute Leukemias of Ambiguous Lineage
Acute Myeloid Leukemia/Transient Myeloproliferative Disorder
Acute Undifferentiated Leukemia
Aggressive NK-cell Leukemia
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blastic Phase Chronic Myelogenous Leukemia
Childhood Chronic Myelogenous Leukemia
Chronic Phase Chronic Myelogenous Leukemia
Mast Cell Leukemia

Interventions: Drug: Akt inhibitor MK2206
Other: diagnostic laboratory biomarker analysis
Other: pharmacological study

First Posted Date: 2010-11-01

Last Posted Date: 2014-04-29

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 45

Registration Number: NCT01231919

Locations: 🇺🇸
Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
🇨🇦
Hospital for Sick Children, Toronto, Ontario, Canada
🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States

and more 22 locations

Clinical And Translational Study Of MK-2206 In Patients With Metastatic KRAS-Wild-Type, PIK3CA-Mutated, Colorectal Cancer

Phase 2

Terminated

Conditions: Colon Cancer
Rectal Cancer

Interventions: Drug: MK-2206

First Posted Date: 2010-08-23

Last Posted Date: 2015-11-18

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 1

Registration Number: NCT01186705

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy